Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients
Table 2
Association of BRCA1 promoter methylation with clinicopathological parameters.
Overall ()
%
BRCA1 methylation in normal tissues
BRCA1 methylation in cancer tissues
Methylated (14)
Unmethylated (26)
value
Methylated (17)
Unmethylated (23)
value
Freq.
(%)
Freq.
(%)
Freq.
(%)
Freq.
(%)
Age:
<50
10
25%
6
(42.9)
4
(15.4)
0.123
5
(29.4)
5
(21.7)
0.717
≥50
30
75%
8
(57.1)
22
(84.6)
12
(70.6)
18
(78.3)
Menopausal status:
Premenopause
7
17.5%
5
(35.7)
2
(7.7)
5
(29.4)
2
(8.7)
0.113
Postmenopause
33
82.5%
9
(64.3)
24
(92.3)
12
(70.6)
21
(91.3)
Age at menopause:
≤50
28
70.0%
8
(57.1)
20
(76.9)
0.079
10
(58.8)
18
(78.3)
0.317
>50
5
12.5%
1
(7.1)
4
(15.4)
2
(11.8)
3
(13.0)
Premenopausal
7
17.5%
5
(35.7)
2
(7.7)
5
(29.4)
2
(8.7)
Mean ± SD
49.2 ± 3.7
50.1 ± 2.8
48.8 ± 3.9
0.318
50.7 ± 3.1
48.3 ± 3.4
0.048
Tumor size:
T1
4
10.0%
2
(14.3)
2
(7.7)
0.478
1
(5.9)
3
(13.0)
0.800
T2
28
70.0%
11
(78.6)
17
(65.4)
13
(76.5)
15
(65.2)
T3
4
10.0%
1
(7.1)
3
(11.5)
2
(11.8)
2
(8.7)
T4
4
10.0%
0
(0)
4
(15.4)
1
(5.9)
3
(13.0)
Lymph node status:
N0
11
27.5%
5
(35.7)
6
(23.1)
0.478
5
(29.4)
6
(26.1)
0.544
N1
8
20.0%
4
(28.6)
4
(15.4)
5
(29.4)
3
(13.0)
N2
13
32.5%
3
(21.4)
10
(38.5)
4
(23.5)
9
(39.1)
N3
8
20.0%
2
(14.3)
6
(23.1)
3
(17.6)
5
(21.7)
Clinical stage:
I
2
5.0%
2
(14.3)
0
(0.0)
0.124
1
(5.9)
1
(4.3)
0.940
IIA
10
25.0%
4
(28.6)
6
(23.1)
4
(23.5)
6
(26.1)
IIB
13
32.5%
6
(42.9)
7
(26.9)
7
(41.2)
6
(26.1)
IIIA
4
10.0%
0
(0.0)
4
(15.4)
1
(5.9)
3
(13.0)
IIIB
3
7.5%
0
(0.0)
3
(11.5)
1
(5.9)
2
(8.7)
IIIC
8
20.0%
2
(14.3)
6
(23.1)
3
(17.6)
5
(21.7)
Histological grade:
G1
3
7.5%
1
(7.1)
2
(7.1)
0.319
2
(11.8)
1
(4.3)
0.281
G2
30
75.0%
11
(78.6)
19
(73.1)
14
(82.4)
16
(69.6)
G3
3
7.5%
2
(14.3)
1
(3.8)
1
(5.9)
2
(8.7)
No grade
4
10.0%
0
(0.0)
4
(15.4)
0
(0.0)
4
(17.4)
Chi-square exact test is statistically significant at 95% confidence level.
